Clinical Trial Update: Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas [Phase 1, Phase 2]

View source ↗

Summary

This update covers a Phase 1/Phase 2 evaluation of fourth-generation safety-designed CAR T cells targeting high-risk and refractory B-cell lymphomas. The sponso…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma

Drugs mentioned

• Fourth-generation safety-designed CAR T cells

Snippet

Sponsor: Peking University | Conditions: B-cell Lymphomas | Phase 1, Phase 2 | Status: UNKNOWN